MEDEXUS PHARMACEUTICALS INC (MDP.CA) Fundamental Analysis & Valuation
TSX:MDP • CA58410Q2036
3.1 CAD
0 (0%)
Last: Mar 9, 2026, 07:00 PM
This MDP.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Overall MDP gets a fundamental rating of 4 out of 10. We evaluated MDP against 34 industry peers in the Pharmaceuticals industry. MDP has only an average score on both its financial health and profitability. MDP is not valued too expensively and it also shows a decent growth rate.
1. MDP.CA Profitability Analysis
1.1 Basic Checks
- MDP had negative earnings in the past year.
- In the past year MDP had a positive cash flow from operations.
- In multiple years MDP reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: MDP reported negative operating cash flow in multiple years.
1.2 Ratios
- The Return On Assets of MDP (-0.18%) is better than 70.59% of its industry peers.
- MDP has a Return On Equity of -0.52%. This is in the better half of the industry: MDP outperforms 70.59% of its industry peers.
- MDP has a Return On Invested Capital of 3.02%. This is in the better half of the industry: MDP outperforms 70.59% of its industry peers.
- MDP had an Average Return On Invested Capital over the past 3 years of 9.89%. This is in line with the industry average of 8.22%.
- The 3 year average ROIC (9.89%) for MDP is well above the current ROIC(3.02%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.18% | ||
| ROE | -0.52% | ||
| ROIC | 3.02% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
- MDP has a better Operating Margin (3.91%) than 73.53% of its industry peers.
- MDP's Gross Margin of 53.87% is amongst the best of the industry. MDP outperforms 82.35% of its industry peers.
- MDP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.91% | ||
| PM (TTM) | N/A | ||
| GM | 53.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. MDP.CA Health Analysis
2.1 Basic Checks
- MDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- MDP has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, MDP has more shares outstanding
- MDP has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 0.66, we must say that MDP is in the distress zone and has some risk of bankruptcy.
- MDP's Altman-Z score of 0.66 is fine compared to the rest of the industry. MDP outperforms 64.71% of its industry peers.
- MDP has a debt to FCF ratio of 1.48. This is a very positive value and a sign of high solvency as it would only need 1.48 years to pay back of all of its debts.
- MDP's Debt to FCF ratio of 1.48 is amongst the best of the industry. MDP outperforms 91.18% of its industry peers.
- MDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.35, MDP perfoms like the industry average, outperforming 52.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.48 | ||
| Altman-Z | 0.66 |
ROIC/WACC0.33
WACC9.29%
2.3 Liquidity
- A Current Ratio of 1.12 indicates that MDP should not have too much problems paying its short term obligations.
- MDP's Current ratio of 1.12 is on the low side compared to the rest of the industry. MDP is outperformed by 79.41% of its industry peers.
- MDP has a Quick Ratio of 1.12. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
- MDP has a worse Quick ratio (0.62) than 79.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.62 |
3. MDP.CA Growth Analysis
3.1 Past
- The earnings per share for MDP have decreased strongly by -112.14% in the last year.
- Looking at the last year, MDP shows a decrease in Revenue. The Revenue has decreased by -9.23% in the last year.
- The Revenue has been growing slightly by 7.82% on average over the past years.
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
3.2 Future
- Based on estimates for the next years, MDP will show a very strong growth in Earnings Per Share. The EPS will grow by 53.29% on average per year.
- Based on estimates for the next years, MDP will show a quite strong growth in Revenue. The Revenue will grow by 10.80% on average per year.
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. MDP.CA Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for MDP. In the last year negative earnings were reported.
- A Price/Forward Earnings ratio of 7.07 indicates a rather cheap valuation of MDP.
- Based on the Price/Forward Earnings ratio, MDP is valued cheaply inside the industry as 85.29% of the companies are valued more expensively.
- MDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.65, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.07 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MDP is valued cheaper than 85.29% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, MDP is valued cheaply inside the industry as 91.18% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.3 | ||
| EV/EBITDA | 6.19 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as MDP's earnings are expected to grow with 109.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y101%
EPS Next 3Y109.18%
5. MDP.CA Dividend Analysis
5.1 Amount
- No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MDP.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:MDP (3/9/2026, 7:00:00 PM)
3.1
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2026-02-11/amc
Earnings (Next)N/A N/A
Inst Owners0.65%
Inst Owner ChangeN/A
Ins Owners7.65%
Ins Owner ChangeN/A
Market Cap100.13M
Revenue(TTM)99.43M
Net Income(TTM)-272.00K
Analysts82.5
Price Target7.03 (126.77%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.21%
Min EPS beat(2)0.99%
Max EPS beat(2)107.43%
EPS beat(4)4
Avg EPS beat(4)77.72%
Min EPS beat(4)0.99%
Max EPS beat(4)144%
EPS beat(8)7
Avg EPS beat(8)78.39%
EPS beat(12)9
Avg EPS beat(12)100.87%
EPS beat(16)11
Avg EPS beat(16)73.38%
Revenue beat(2)0
Avg Revenue beat(2)-2.26%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-0.29%
Revenue beat(4)0
Avg Revenue beat(4)-1.39%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)-0.29%
Revenue beat(8)2
Avg Revenue beat(8)-0.34%
Revenue beat(12)4
Avg Revenue beat(12)-1.11%
Revenue beat(16)7
Avg Revenue beat(16)0.69%
PT rev (1m)11.09%
PT rev (3m)11.47%
EPS NQ rev (1m)50%
EPS NQ rev (3m)50%
EPS NY rev (1m)85.71%
EPS NY rev (3m)81.82%
Revenue NQ rev (1m)0.82%
Revenue NQ rev (3m)1.21%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.07 | ||
| P/S | 0.74 | ||
| P/FCF | 4.3 | ||
| P/OCF | 4.25 | ||
| P/B | 1.41 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.19 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.44
Fwd EY14.15%
FCF(TTM)0.72
FCFY23.25%
OCF(TTM)0.73
OCFY23.53%
SpS4.18
BVpS2.19
TBVpS-0.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.18% | ||
| ROE | -0.52% | ||
| ROCE | 4.2% | ||
| ROIC | 3.02% | ||
| ROICexc | 3.61% | ||
| ROICexgc | 107.26% | ||
| OM | 3.91% | ||
| PM (TTM) | N/A | ||
| GM | 53.87% | ||
| FCFM | 17.26% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.48 | ||
| Debt/EBITDA | 1.33 | ||
| Cap/Depr | 2.1% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 1.57 | ||
| Cash Conversion | 127.65% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.62 | ||
| Altman-Z | 0.66 |
F-Score5
WACC9.29%
ROIC/WACC0.33
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%
EBIT growth 1Y-74.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.75%
EBIT Next 3Y62.94%
EBIT Next 5Y44.59%
FCF growth 1Y-17.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.2%
OCF growth 3YN/A
OCF growth 5YN/A
MEDEXUS PHARMACEUTICALS INC / MDP.CA FAQ
What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MDP.CA.
What is the valuation status of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a valuation rating of 6 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for MEDEXUS PHARMACEUTICALS INC?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 5 / 10.
What is the financial health of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.